TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21592984

Group type: EXPERIMENTAL
Intervention: TBEV vaccine
Number of subjects: 0
Study: 21593054

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21593354

Group type: EXPERIMENTAL
Intervention: FLVCR1 expression
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: BCRP expression
Number of subjects: 71
Study: 21593494

Group type: EXPERIMENTAL
Intervention: Late follicular phase (high estradiol) in fed state
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Late follicular phase (high estradiol) in fasting state
Number of subjects: 9

Group type: COMPARATOR
Intervention: Early follicular phase (low estradiol) in fed state
Number of subjects: 9

Group type: COMPARATOR
Intervention: Early follicular phase (low estradiol) in fasting state
Number of subjects: 9
Study: 21593507

Group type: EXPERIMENTAL
Intervention: Eucaloric reduced-carbohydrate (RedCHO)/higher-fat diet (43% carbohydrate, 39% fat)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Eucaloric standard diet (55% carbohydrate, 27% fat)
Number of subjects: 69
Study: 21595953

Group type: EXPERIMENTAL
Intervention: Super-selective arterial infusion of gemcitabine over 24 hours via subcutaneous indwelling port.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Super-selective arterial infusion of gemcitabine.
Number of subjects: 27
Study: 21596084

Group type: EXPERIMENTAL
Intervention: VAX125 vaccine at a dose of 5 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: VAX125 vaccine at a dose of 8 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined 5 and 8 μg groups
Number of subjects: 120
Study: 21596321

Group type: EXPERIMENTAL
Intervention: Attenuated plaque (hypoechoic or mixed atheroma with ultrasound attenuation without calcification)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Attenuated plaque
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Mean attenuation score
Number of subjects: 364
Study: 21596852

Group type: EXPERIMENTAL
Intervention: RVDD (lenalidomide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), dexamethasone 20/10 mg)
Number of subjects: 72
Study: 21600049

Group type: EXPERIMENTAL
Intervention: IMRT and carbon ion boost (24 GyE carbon ions in 8 fractions and IMRT 50 Gy at 2.0 Gy/fraction)
Number of subjects: 30
Study: 21600054

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21604935

Group type: EXPERIMENTAL
Intervention: Active annual screening program of PSA screening for six rounds, four of which had accompanying digital rectal examination (DRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patterns of screening occurring in the population in many academic and community settings across the USA
Number of subjects: 0
Study: 21605131

Group type: EXPERIMENTAL
Intervention: Atrial tachycardia/atrial fibrillation (AT/AF)
Number of subjects: 537

Group type: COMPARATOR
Intervention: No atrial tachycardia/atrial fibrillation (AT/AF)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: High average ventricular rate (≥110 beats per minute) during AT/AF
Number of subjects: 537

Group type: COMPARATOR
Intervention: Normal average ventricular rate during AT/AF
Number of subjects: 537
Study: 21605453

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Remote ischemic pre- and postconditioning
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study: 21606164

Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Horse anti-thymocyte globulin (historical control)
Number of subjects: 20
Study: 21606224

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 142
Study: 21606412

Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184) 175 mg daily
Number of subjects: 37
Study: 21606542

Group type: EXPERIMENTAL
Intervention: MVA85A (2.5 × 10(7) plaque-forming units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA85A (5 × 10(7) plaque-forming units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA85A (10 × 10(7) plaque-forming units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21607190

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel
Number of subjects: 30
Study: 21607562

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation (2 sessions/day during hospitalization, 15 ± 1 training sessions)
Number of subjects: 19
Study: 21607774

Group type: EXPERIMENTAL
Intervention: High-dose rate balloon brachytherapy (HDRBB) delivering 34 Gy in 10 fractions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3D conformal external beam irradiation (3D-CRT) consisting of 38.5 Gy in 10 fractions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Local toxicity assessment
Number of subjects: 8
Study: 21609134

Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT administered by intramuscular injection at doses of 6.0×10(11), 1.9×10(12), and 6.0×10(12) vector genomes/kg (n=3 subjects/dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT
Number of subjects: 9
Study: 21610204

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2042
Study: 21611722

Group type: EXPERIMENTAL
Intervention: Computerized tomographic cisternography (CTC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Shunt insertion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Preoperative iNPH grading scale-R scores
Number of subjects: 70
Study: 21612620

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment for Upper Extremity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kinematic analysis of arm movements (computer-based objective methods)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ABILHAND questionnaire of manual ability
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spasticity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Passive range of motion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Impact on Participation and Autonomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EuroQol Quality of Life Scale
Number of subjects: 120
Study: 21612646

Group type: EXPERIMENTAL
Intervention: donepezil 23 mg/d
Number of subjects: 1434

Group type: COMPARATOR
Intervention: donepezil 10 mg/d
Number of subjects: 1434
Study: 21612781

Group type: EXPERIMENTAL
Intervention: CKD-EPI equation
Number of subjects: 15773

Group type: COMPARATOR
Intervention: MDRD Study equation
Number of subjects: 15773
Study: 21612836

Group type: EXPERIMENTAL
Intervention: NGX-4010, capsaicin 8% patch
Number of subjects: 117
Study: 21613261

Group type: EXPERIMENTAL
Intervention: Decitabine delivered at 20 mg/m² by 1-hour infusion (Arm A) for 3, 5, or 7 days before standard induction chemotherapy.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Decitabine delivered at 20 mg/m² by continuous infusion (Arm B) for 3, 5, or 7 days before standard induction chemotherapy.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard induction chemotherapy with infusional cytarabine (100 mg/m² for 7 days) and daunorubicin (60 mg/m² × 3 doses).
Number of subjects: 27
Study: 21613319

Group type: EXPERIMENTAL
Intervention: Maximum carotid intima-media thickness (CIMT) measurement
Number of subjects: 3364
Study: 21613559

Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose-sweetened beverages
Number of subjects: 0
Study: 21617560

Group type: EXPERIMENTAL
Intervention: Bowel Habit Questionnaire (BHQ)
Number of subjects: 416
Study: 21619642

Group type: EXPERIMENTAL
Intervention: Vaccination in Paarl
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Vaccination in Rietvlei
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Vaccination in Umlazi
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Incomplete vaccination in Rietvlei compared to Paarl
Number of subjects: 1137
Study: 21619670

Group type: EXPERIMENTAL
Intervention: Fara'd dates (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lulu dates (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bo ma'an dates (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dabbas dates (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Khalas dates (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fara'd dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lulu dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bo ma'an dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dabbas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Khalas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 23
Study: 21619692

Group type: EXPERIMENTAL
Intervention: Brazil nuts (BNG), n = 8, 15-25 g/day (equivalent to 3 to 5 units/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Brazil nuts (BNG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PG, lactose), n = 9, one capsule/day
Number of subjects: 17
Study: 21620357

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 123
Study: 21620511

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate plus topotecan
Number of subjects: 9
Study: 21620645

Group type: EXPERIMENTAL
Intervention: Victoria Bowel Performance Scale (BPS)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (new nursing assessment tools)
Number of subjects: 192
Study: 21621166

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 21
Study: 21621668

Group type: EXPERIMENTAL
Intervention: Prone instability test (PIT) performed by examiners
Number of subjects: 30
Study: 21622693

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 µg)
Number of subjects: 682
Study: 21623265

Group type: EXPERIMENTAL
Intervention: Crizotinib (PF02341066), a dual MET and ALK inhibitor; specific dosage and duration not mentioned.
Number of subjects: 1
Study: 21623649

Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (9 μg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vitamin B12 injections
Number of subjects: 44
Study: 21623761

Group type: EXPERIMENTAL
Intervention: AICDA expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-length isoform AICDA
Number of subjects: 0
Study: 21624046

Group type: EXPERIMENTAL
Intervention: High PAI-1 activity (≥ 75th percentile)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High levels of t-PA antigen (≥ 75th percentile)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Changes in levels of F(1+2)
Number of subjects: 199
Study: 21626286

Group type: EXPERIMENTAL
Intervention: Polysomnography screening for obstructive sleep apnea (OSA)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Polysomnography screening for OSA
Number of subjects: 132
Study: 21627839

Group type: EXPERIMENTAL
Intervention: Carboplatin plus celecoxib (400 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Carboplatin plus celecoxib
Number of subjects: 45
Study: 21628633

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 μg/d) for 3 years
Number of subjects: 438

Group type: COMPARATOR
Intervention: No phylloquinone supplementation
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Phylloquinone-supplemented group
Number of subjects: 438
Study: 21628721

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype with clinical variables
Number of subjects: 1069
Study: 21630308

Group type: EXPERIMENTAL
Intervention: CRd (cyclophosphamide, lenalidomide, and dexamethasone)
Number of subjects: 53
Study: 21630312

Group type: EXPERIMENTAL
Intervention: Laboratory and echocardiography markers
Number of subjects: 0
Study: 21631213

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 27
Study: 21631321

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in subjects with traumatic brain injury
Number of subjects: 63

Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in controls (21 military personnel with blast exposure but no clinical diagnosis of traumatic brain injury)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Follow-up DTI scans in subjects with traumatic brain injury
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DTI findings in subjects with traumatic brain injury
Number of subjects: 63
Study: 21632834

Group type: EXPERIMENTAL
Intervention: Automatic continuous positive airway pressure devices
Number of subjects: 0
Study: 21632852

Group type: EXPERIMENTAL
Intervention: Aflibercept (given intravenously every two weeks until disease progression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 0
Study: 21632855

Group type: EXPERIMENTAL
Intervention: Initial TIL outgrowth
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Age ≤30 years
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 226

Group type: COMPARATOR
Intervention: Systemic therapy 30 days before tumor harvest
Number of subjects: 226

Group type: COMPARATOR
Intervention: Biochemotherapy within 0 to 60 days of tumor harvest
Number of subjects: 226
Study: 21633906

Group type: EXPERIMENTAL
Intervention: Bortezomib (a 26S proteasome inhibitor)
Number of subjects: 0
Study: 21635145

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment in healthy volunteers
Number of subjects: 0
Study: 21636665

Group type: EXPERIMENTAL
Intervention: African American patients with COPD experiencing exacerbations
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: African American patients with COPD experiencing hospitalized exacerbations
Number of subjects: 1273

Group type: COMPARATOR
Intervention: African American patients with COPD without exacerbations
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Caucasian patients with COPD without exacerbations
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: African American patients with COPD
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Caucasian patients with COPD
Number of subjects: 1273
Study: 21638133

Group type: EXPERIMENTAL
Intervention: Screen-detected type 2 diabetes
Number of subjects: 6041

Group type: EXPERIMENTAL
Intervention: Impaired glucose regulation (IGR)
Number of subjects: 6041

Group type: EXPERIMENTAL
Intervention: Undiagnosed glucose disorders
Number of subjects: 6041

Group type: EXPERIMENTAL
Intervention: South Asian population
Number of subjects: 6041
Study: 21639407

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg, uptitrated to OM 40 mg, followed by hydrochlorothiazide (HCTZ) 12.5-25 mg at 3-week intervals
Number of subjects: 178
Study: 21639874

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin with >/= 50% pain improvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin with pain score <30 mm on VAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin with both >/= 50% pain improvement and pain score <30 mm on VAS
Number of subjects: 0
Study: 21642245

Group type: EXPERIMENTAL
Intervention: Adenoviral vector encoding human IFN-α (Ad.IFN-α2b) administered intrapleurally, two doses.
Number of subjects: 9
Study: 21642514

Group type: EXPERIMENTAL
Intervention: Neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles)
Number of subjects: 23
Study: 21642685

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate, 400 mg orally twice daily
Number of subjects: 28
Study: 21645184

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 208
Study: 21645894

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21646032

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride (Kuvan®) at a mean dose of 16.2±4.7 mg/kg/day for an average exposure of 658.7±221.3 days.
Number of subjects: 111
Study: 21646941

Group type: EXPERIMENTAL
Intervention: Evaporative skin cooling devices at 30°C
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standardized exercise on a bicycle ergometer at ambient temperatures of 25 and 30°C without cooling
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standardized exercise on a bicycle ergometer at ambient temperatures of 25 and 30°C
Number of subjects: 13
Study: 21648278

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 7998

Group type: COMPARATOR
Intervention: Obese boys
Number of subjects: 7998

Group type: COMPARATOR
Intervention: Obese girls
Number of subjects: 7998
Study: 21648284

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) stimulation testing with arginine and GH releasing hormone
Number of subjects: 10
Study: 21649541

Group type: EXPERIMENTAL
Intervention: Enzastaurin (250 mg twice daily)
Number of subjects: 25
Study: 21649849

Group type: EXPERIMENTAL
Intervention: Transfusion of stored platelets
Number of subjects: 0
Study: 21651873

Group type: EXPERIMENTAL
Intervention: Bispebjerg Early Warning Score (BEWS) ≥ 5
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bispebjerg Early Warning Score (BEWS)
Number of subjects: 300
Study: 21652249

Group type: EXPERIMENTAL
Intervention: Lean mass measurement
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Fat mass measurement in women
Number of subjects: 134
Study: 21653528

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV) Study
Number of subjects: 0
Study: 21653649

Group type: EXPERIMENTAL
Intervention: Informed consent comprehension quiz
Number of subjects: 525
Study: 21653689

Group type: EXPERIMENTAL
Intervention: Erlotinib (125 mg/m²/day for children, 90 mg/m²/day for adults)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 88
Study: 21653800

Group type: EXPERIMENTAL
Intervention: Processed meat consumption (highest quintile)
Number of subjects: 40291

Group type: EXPERIMENTAL
Intervention: Fresh red meat consumption (highest quintile)
Number of subjects: 40291
Study: 21657861

Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone (0.15 mg/kg initial dose, adjusted to 0.3 mg/kg or 0.075 mg/kg as needed, maximum one dose per 24 hours)
Number of subjects: 82

Group type: COMPARATOR
Intervention: DB placebo
Number of subjects: 82
Study: 21658885

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting self-expanding nitinol stent
Number of subjects: 104
Study: 21659356

Group type: EXPERIMENTAL
Intervention: Treosulfan (3×14 g/m²) and Fludarabine (5×30 mg/m²)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Treosulfan and Fludarabine
Number of subjects: 45
Study: 21659363

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m(2)/day intravenously over one hour for five consecutive days every four weeks
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Decitabine treatment
Number of subjects: 101
Study: 21659625

Group type: EXPERIMENTAL
Intervention: Semi-mechanistic nonlinear disease progression model using covariates
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Covariates affecting baseline disease status
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Covariates influencing disease progression rate
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Comparison of disease progression rates
Number of subjects: 191
Study: 21659657

Group type: EXPERIMENTAL
Intervention: 32 single-nucleotide polymorphisms (SNPs) in or near 17 genes in 11 previously identified genome-wide significant (GWS) spirometric genomic regions.
Number of subjects: 5456

Group type: EXPERIMENTAL
Intervention: Dense panel of imputed HapMap2 SNP markers from the 17 genes located near the 32 GWS SNPs and in a set of 21 well-studied COPD candidate genes.
Number of subjects: 5456
Study: 21663862

Group type: EXPERIMENTAL
Intervention: Weekly topotecan (6 mg/m(2) I.V. for 6 weeks)
Number of subjects: 38
Study: 21664205

Group type: EXPERIMENTAL
Intervention: Free flap skin temperature assessment using a digital infrared surface thermometer (Medisana FTD, Germany)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Microcirculatory assessment using Laser-Doppler and photospectrometry (Oxygen-to-see, Lea Medizintechnik, Germany)
Number of subjects: 54
Study: 21664608

Group type: EXPERIMENTAL
Intervention: Smoking (bipolar patients)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lifetime history of alcohol dependence/abuse
Number of subjects: 102

Group type: COMPARATOR
Intervention: History of drug use
Number of subjects: 102

Group type: COMPARATOR
Intervention: Age of illness onset
Number of subjects: 102
Study: 21666249

Group type: EXPERIMENTAL
Intervention: Urinary N-acetyl-beta-D-glucosaminidase (NAG)
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Kidney injury molecule 1 (KIM-1)
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL)
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Combination of impaired eGFR, increased UACR, and high NAG
Number of subjects: 2130